Qui Tran

Qui Tran

Auto-generated profile, based on publicly available information

Qui Tran

Amgen Inc, Thousand Oaks, CA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
GDGrace K. Dy
Grace K. Dy
RGRamaswamy Govindan
Ramaswamy Govindan
VVVamsidhar Velcheti
Vamsidhar Velcheti
GFGerald S. Falchook
Gerald S. Falchook
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
BLBob T. Li
Bob T. Li
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In the longest follow-up, to our knowledge, for a KRASG12C inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with KRAS G12C-mutated advanced non–small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883 ). This multicenter, single-group, open-label phase I/phase II trial enrolled 174 patients with KRAS G12C-mutated, locally advanced or metastatic NSCLC after progression on prior therapies. Patients (N = 174) received sotorasib 960 mg once daily with the primary end points for phase I of safety and tolerability and for phase II of objective response rate (ORR). Sotorasib produced an ORR of 41%, median duration of response of 12.3 months, progression-free survival (PFS) of 6.3 months, overall survival (OS) of 12.5 months, and 2-year OS rate of 33%. Long-term clinical benefit (PFS ≥ 12 months) was observed in 40 (23%) patients across PD-L1 expression levels, in a proportion of patients with somatic STK11 and/or KEAP1 alterations, and was associated with lower baseline circulating tumor DNA levels. Sotorasib was well tolerated, with few late-onset treatment-related toxicities, none of which led to treatment discontinuation. These results demonstrate the long-term benefit of sotorasib, including in subgroups with poor prognosis.

21 August 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
EJElias Jabbour
Elias Jabbour
NGNicola Gökbuget
Nicola Gökbuget
HKHagop M. Kantarjian
Hagop M. Kantarjian
XTXavier Thomas
Xavier Thomas
RLRichard A. Larson
Richard A. Larson
ASAnthony S. Stein
Anthony S. Stein

5 April 2019 in Leukemia & Lymphoma
Verified
Journal Article
Open access
HDHervé Dombret
Hervé Dombret
MTMax S. Topp
Max S. Topp
ASAndre C. Schuh
Andre C. Schuh
AWAndrew H. Wei
Andrew H. Wei
SDSimon Durrant
Simon Durrant
HKHagop Kantarjian
Hagop Kantarjian
Outcomes for adults with relapsed/refractory acute lymphoblastic leukemia (ALL) are poor with chemotherapy, particularly in later salvage. The TOWER study examined survival, remission, bridge to allogeneic hematopoietic stem cell transplantation (HSCT), and safety with blinatumomab versus chemotherapy. This report examined outcomes separately for study treatment as first or later salvage. Adults with Philadelphia chromosome-negative B-cell precursor ALL relapsed/refractory to chemotherapy were randomly assigned 2:1 to receive blinatumomab by continuous infusion for 4 weeks in 6-week cycles, or standard salvage chemotherapy. Overall survival for blinatumomab versus chemotherapy was higher both in first salvage and in later salvage. Safety was similar between patients in first salvage and those in later salvage. Blinatumomab as later salvage was associated with higher complete remission rates and served as a bridge to allogeneic HSCT, supporting the use of blinatumomab in both settings. This study is registered at www.clinicaltrials.gov as #NCT02013167.

1 July 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
FPFilippo Pietrantonio
Filippo Pietrantonio
LSLisa Salvatore
Lisa Salvatore
TETaito Esaki
Taito Esaki
DMDominik Paul Modest
Dominik Paul Modest
DLDavid Paez Lopez-Bravo
David Paez Lopez-Bravo
MFMarwan Fakih
Marwan Fakih
In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.

28 June 2018 in Blood
Verified
Journal Article
Open access
PDF file
MTMax S. Topp
Max S. Topp
ZZZachary Zimmerman
Zachary Zimmerman
PCPaul Cannell
Paul Cannell
HDHervé Dombret
Hervé Dombret
JMJohan Maertens
Johan Maertens
Andre C. SchuhAndre C. Schuh
Andre C. Schuh
Key Points: Blinatumomab delays deterioration in HRQL in adults with R/R ALL.

28 June 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
ASAnthony S. Stein
Anthony S. Stein
RLRichard A. Larson
Richard A. Larson
ASAndre C. Schuh
Andre C. Schuh
WSWilliam Stevenson
William Stevenson
ELEwa Lech-Marańda
Ewa Lech-Marańda
MTMax S. Topp
Max S. Topp
Key Points: In the phase 3 TOWER study, exposure-adjusted AE rates were lower for blinatumomab vs SOC chemotherapy in Ph− B-cell r/r ALL patients. These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for B-cell r/r ALL patients.